Fulcrum Therapeutics Inc. (FULC) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results
May 9, 2022 7:00 AM EDTInitial data from Phase 1b trial of FTX-6058 in sickle cell disease to be presented at the EHA 2022 CongressÂ
Phase 3 REACH trial of losmapimod in FSHD expected to begin in 2Q 2022
Conference call scheduled for 8:00 a.m. ET today
CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics,... More
